Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00137111
Other study ID # TOTXV
Secondary ID R37CA036401P30CA
Status Completed
Phase Phase 3
First received
Last updated
Start date July 8, 2000
Est. completion date April 2014

Study information

Verified date September 2020
Source St. Jude Children's Research Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective is to estimate the overall event-free survival of children at least one year of age at diagnosis who are treated with risk-directed therapy and to monitor the molecular remission induction rate.


Description:

Read more »
Read more »

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Prednisone, Dexamethasone, Vincristine, Daunorubicin
See Detailed Description sections for details on treatment interventions.
Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase
See Detailed Description sections for details on treatment interventions.
Methotrexate, Cyclophosphamide, Cytarabine, Etoposide
See Detailed Description sections for details on treatment interventions.
Mercaptopurine, Imatinib
See Detailed Description sections for details on treatment interventions.
Procedure:
chemotherapy, intrathecal chemotherapy
See Detailed Description sections for details on treatment interventions.
steroid therapy, hematopoietic stem cell transplantation
See Detailed Description sections for details on treatment interventions.

Locations

Country Name City State
United States Cook Children's Medical Center Fort Worth Texas
United States St Jude Children's Research Hospital Memphis Tennessee

Sponsors (2)

Lead Sponsor Collaborator
St. Jude Children's Research Hospital National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (199)

See more »

Outcome

Type Measure Description Time frame Safety issue
Other Median Difference in CASP1 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs Glucocorticoid-sensitive Cells Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of CASP1 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. Pre-treatment
Other Median Difference in NLRP3 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs. Glucocorticoid-sensitive Cells Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of NLRP3 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. Pre-treatment
Primary Overall Event-free Survival (EFS) EFS was measured from the start of on-study to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Failure to enter remission was considered an event at time zero. Measurement was determined by Kaplan-Meyer estimate. Median follow-up time (range) 5.6 (1.3 to 8.9) years
Primary Continuous Complete Remission Since Week 56 Therapy. CCR was measured from end of week 56 therapy to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Measurement was determined by Kaplan-Meyer estimate. Median follow up time (range) 4.5 (1 to 7.8) years
Secondary Minimal Residual Disease (MRD) Detection of MRD at end of induction where positive MRD was defined as one or more leukemic cell per 10,000 mononuclear bone-marrow cells (>=0.01%). End of Induction (Day 46 MRD measurement)
Secondary Mean Difference of Active Methotrexate Polyglutamates (MTXPG) in Leukemia Cells Between Two Arms (4 Hours vs. 24 Hours). Children were randomly assigned to receive initial single-agent treatment with HDMTX (1g/m^2) as either a 24-hour infusion or a 4-hour infusion and the outcome measure was the accumulation of MTXPG in leukemia cells. 42 hours after start of high dose methotrexate infusion (HDMTX)
Secondary Circulating Leukemia Cells in Peripheral Blood Change From Prior to the Methotrexate Infusion to Three Days After Between Two Arms (4 Hours vs. 24 Hours) White blood cell (leukocytes) counts in peripheral blood by Complete Blood Count
Measurement: Percentage change of leukemia cells from baseline
Immediately before the methotrexate infusion and three days after subsequent infusion
See also
  Status Clinical Trial Phase
Completed NCT00391989 - Treatment of Adult Ph+ LAL With BMS-354825 Phase 2
Recruiting NCT00131053 - Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL) Phase 2
Recruiting NCT00131027 - High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL) Phase 3
Completed NCT00995137 - Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia Phase 1
Terminated NCT01100658 - Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors N/A
Recruiting NCT02879643 - Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL Phase 1
Terminated NCT00798213 - SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED) Phase 2
Recruiting NCT02888977 - Tyrosine Kinase Inhibitors and Low Intensity Chemotherapy in Ph+ ALL
Terminated NCT01186328 - EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) Phase 1
Completed NCT00114348 - ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia Phase 4